🟢 Femasys is trading 11.72% up today after FDA approval of modular PMA pathway

Femasys is trading 11.72% up now at $3.05 after the FDA approved a modular PMA pathway for investigational FemBloc.

• The pathway lets the FDA review completed application sections before final clinical data, reducing regulatory uncertainty while the pivotal trial continues.
• The decision advances potential U.S. approval but does not authorize FemBloc marketing.
• Broader biotech strength provides additional supportive context.